Other Events ·
Sangamo Therapeutics, Inc., which filed for Chapter 11 bankruptcy protection on June 23, 2026, has filed its monthly…
SGMOSangamo Therapeutics, Inc
Sangamo Therapeutics, Inc., which filed for Chapter 11 bankruptcy protection on June 23, 2026, has filed its monthly operating report with the U.S. Bankruptcy Court for the period ending June 30, 2026. The company reported a cash balance of $14.4 million at month-end and total assets of $153.1 million against liabilities of $89.2 million. During the reporting period, Sangamo generated $109,000 in gross income while incurring $3.8 million in net losses, primarily driven by reorganization items. The company maintains 73 full-time employees and continues to trade on the OTC Markets under the symbol SGMOQ following its delisting from Nasdaq. Sangamo Therapeutics operates as a biotechnology company focused on developing gene editing therapies.